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Abstract: A 9-year-old girl was severely injured in a car accident in Afghanistan, in which both 
her lower legs were badly damaged. She was treated at the Hospital of Ingolstadt (Klinikum 
Ingolstadt) after she had undergone initial surgery at an Indian hospital. Various bacterial species 
were isolated from multiple wounds, and methicillin-resistant Staphylococcus aureus (MRSA) 
was one among them. After the amputation of her lower legs, she developed MRSA sepsis, 
which was successfully treated with a relatively low dosage of ceftaroline (Zinforo®/Teflaro®; 
2×9 mg/kg/d), although the bacterial isolate’s minimal inhibitory concentration (1.5–4 mg/L) 
suggested a decreased susceptibility. In summary, ceftaroline was highly efficient and well 
tolerated by the patient suffering from MRSA sepsis.
Keywords: side effects, susceptibility, ceftaroline, minimal inhibitory concentration, therapy
Case report
In August 2013, a 9-year-old Afghan girl, who had been severely injured in a car accident 
in early 2013, was admitted to a teaching hospital in southeast Germany (Bavaria). Before 
her transfer to Germany, she had undergone surgery at an Indian hospital. Her left leg had 
been stabilized with an external fixation, which was later substituted by a femur nail.
On admission, her general condition dramatically deteriorated. She was dehydrated 
and undernourished (130 cm height, 25 kg body weight) as indicated by decreased 
serum concentration of total protein (42.3 mg/dL [normal range 66.0–83.0 mg/dL]) 
and creatinine (0.3 mg/dL [0.6–0.9 mg/dL]). She also suffered from anemia and sev-
eral decubitus dorsal ulcers (stage 2 and 3). Both legs showed multiple wounds with 
extended areas of scab which secreted large amounts of yellow pus. Pus was also 
secreted from a fistula of her left hip joint.
Various bacteria species exhibiting extensive antibiotic resistances were isolated 
from swabs of the patients wounds: methicillin resistant Staphylococcus aureus (MRSA); 
carbapenem resistant Pseudomonas aeruginosa; and several Gram negative bacteria 
species with extended spectrum beta-lactamase activity (ESBL); Citrobacter sedlakii; 
Escherichia coli; Proteus mirabilis; Klebsiella pneumoniae. Furthermore, methicillin 
susceptible S. aureus, P. mirabilis (non ESBL), Enterococcus faecalis, Enterococcus 
hirae, Bacteroides fragilis, and peptostreptococci were identified. Bacterial identifica-
tion and antibiotic susceptibility testing was performed as recently described.1
After 2 weeks of initial treatment at the intensive care unit, the patient was admitted to 
the pediatric surgery ward as her general condition had significantly improved. Until June 
2014, she underwent 16 surgeries and approximately 60 dressing changes, each requiring 
Correspondence: stefan Borgmann
Department of Infectious Diseases and 
Infection Control, Klinikum Ingolstadt, 
Krumenauer str. 25, D-85049 Ingolstadt, 
Germany
Tel +49 841 880 2020
Fax +49 841 880 2849
email stefan.borgmann@klinikum-ingolstadt.de 
Journal name: Therapeutics and Clinical Risk Management
Article Designation: Case report
Year: 2016
Volume: 12
Running head verso: Borgmann et al
Running head recto: Ceftaroline treatment in children
DOI: http://dx.doi.org/10.2147/TCRM.S99987
Point your SmartPhone at the code above. If you have a  
QR code reader the video abstract will appear. Or use:
http://youtu.be/89BMo8NTGKM
Video abstract





general anesthetics. During her stay, she received the following 
antibiotics in dosages adapted to her body weight: cefazoline 
(1 g two times per day; 2×1 g/d), imipenem (4×0.5 g/d), mero-
penem (3×400 mg/d), ampicillin (3×400 mg/d) + clindamycin 
(3×150 mg/d) intravenously, amoxicillin (3×400 mg/d) + 
clindamycin (3×150 mg/d) orally, ceftazidime (3×1 g/d), 
ceftaroline (Zinforo® [AstraZeneca, London, UK]/Teflaro® 
[Allergan, Dublin, Ireland]; 2×225 mg/d), and cefuroxime 
(2×250 mg/d) (Figure 1A).
MRSA was frequently isolated from various body 
sites within the first 3 weeks after admission (Figure 1B). 
Following two decolonization cycle, MRSA was not found in 
several swabs taken from the nose and throat nor isolated from 
the biopsy specimen taken from September 16, 2013 to March 
20, 2014. There was no further proof of MRSA over this time, 
except for a nose swab taken on March 20, 2014, leading to 
decolonization measures for seven additional days.
On May 16, 2014, MRSA was found in a biopsy sample 
and it was also found afterwards in swabs taken from the 
nose and throat. On June 3, 2014, the patient underwent 
amputation of her lower legs (knee disarticulation) and 
MRSA was detected in a biopsy of the infected limb. After 
surgery, the patient was treated for 9 days in the intensive 
care unit due to a deterioration in her general condition. 
As shown in Figure 2, systemic inflammatory response 
syndrome was present, as indicated by an increased heart 
rate (140/bpm), white blood cell count (.24,200/mm3), 
and decreased blood pressure (systolic arterial pressure 
80–100 mmHg).2 Body temperature rose to 40.3°C and 
C-reactive protein concentration increased to 265.5 mg/L. 
MRSA was found in a blood culture, indicating septic 
infection.
In the following days, antibiotic treatment with ceftaroline 
(2×225 mg/d) led to a continuous improvement of her general 
condition. On June 18, 2014, she underwent a final revision 
surgery of her right thigh wound, including removal of the 
condylar cartilage and debridement of necrotic tissue. Although 
MRSA was detected in a biopsy specimen removed during this 
surgery, there was no increase of inflammation parameters 
nor was the circulation impaired. Ceftaroline application was 
Figure 1 Microbiological results and antibiotic treatment.
Notes: (A) antibiotics applied during hospital stay. (B) Results of microbiological analyses performed during hospital stay with regard to MRsa. swabs were taken from 
nose, throat, nose and throat, axilla, groin, biopsy, wound, blood culture, central vein catheter, urine, and stool. For N/T analysis, two swabs were taken, but the result did 
not discriminate between both swabs.
Abbreviations: a + C, ampicillin/amoxicillin and clindamycin; ax, axilla; BC, blood culture; Bi, biopsy; Cf, ceftazidime; Cr, ceftaroline; Cu, cefuroxime; CVC, central vein 
catheter; Cz, cefazoline; Gr, groin; I, imipenem; iv, intravenous application; M, meropenem; MRsa, methicillin-resistant Staphylococcus aureus; No, nose; N/T, nose and throat; 
or, oral application; st, stool; Th, throat; Ur, urine; Wo, wound.
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stopped after a treatment period of 19 days. No further MRSA 
was found in any of the swabs taken from the nose and throat 
and she was discharged from the hospital in October 2014.
Typing of two MRSA isolates was performed by the 
National Reference Centre for Staphylococci and Enterococci 
at the Robert Koch Institute, Wernigerode, Germany and the 
results are summarized in Table 1. Informed consent was 
given by the patients legal representative. Ethics approval 
was not deemed necessary by the Institutional Review Board 
of Klinikum Ingolstadt as only standard treatment procedures 
were carried out and no additional samples were taken for 
scientific purposes.
Discussion
In this report, we present a young patient with severe infec-
tion of both legs, caused by a multitude of (multiresistant) 
bacteria. Bacteriologic analyses intermittently revealed the 
presence of MRSA, and after amputation surgery, the patient 
Figure 2 Vital signs of the presented patient between May and June 2014.
Notes: Similar to Figure 1, the lowest line shows microbiological results in regard to MRSA finding. MAP was calculated by using the formula: MAP = diastolic blood 
pressure +1/3 (systolic – diastolic blood pressure).
Abbreviations: BC, blood culture; Bi, biopsy; CRp, C-reactive protein; ICU, intensive care unit; Map, mean arterial pressure (mmHg); MRsa, methicillin-resistant 
Staphylococcus aureus; No, nose; N/T, nose and throat; s, surgery; temp, temperature (°C); Th, throat; WBC, white blood cell count.
°
Table 1 Characteristics of MRsa isolates







1 august 15, 2013 Nose t064 CC8 IV– – peN, oXa, GeN, CIp, sXT, MFL 2 (ns) 1.5 (ns)
2 June 3, 2014 Blood culture t064 CC8 IV– – peN, oXa, GeN, CIp, sXT, MFL 4 (ns) 2 (ns)
Notes: aall Staphylococcus aureus strains isolated were typed by analyzing the repetitive X-region of the protein a gene (spa) as described previously.13 bBased on spa-typing 
results, isolates were assigned to clonal complexes reflecting their genetic relatedness among the S. aureus population.13 csCCmec type was investigated as described previously.13 
dThe presence of pVL-encoding lukF-lukS-pV and arca was analyzed by pCR according to strommenger et al.14 eBMD was performed and evaluated according to eUCasT 
guidelines.10,15 fetest (Biomerieux, Nürtingen, Germany) was performed according to the manufacturer’s instructions. gInterpretation of MICs according to eUCasT guidelines.15
Abbreviations: BMD, broth microdilution; CC, clonal complex; CIP, ciprofloxacin; GEN, gentamicin; MFL, moxifloxacin; MIC, minimal inhibitory concentration; 
MRsa, methicillin-resistant Staphylococcus aureus; ns, nonsusceptible; oXa, oxacillin; pCR, polymerase chain reaction; peN, penicillin; pVL, panton–Valentine leukocidin; 
sCC, staphylococcal chromosome cassette; sXT, trimethoprim/sulfamethoxazole.





developed sepsis caused by this particular bacterial species. 
Typing results indicated an endogenous MRSA infection, 
although screening results had suggested successful prior 
MRSA decolonization. Screening and decolonization of 
S. aureus in orthopedic patients is an effective measure to 
prevent endogenous infection and subsequent bacteremia.3 
However, in this case, it is questionable whether decolo-
nization measures proved efficient, due to the underlying 
conditions of the patient. Moreover, the screening results 
presented demonstrate the risk of MRSA recolonization 
in high-risk patients, which underlines the importance of 
continuous MRSA monitoring.
The infection was successfully treated with ceftaroline. 
This antibiotic was chosen because a greater efficiency in 
comparison to vancomycin and linezolid was anticipated. 
Despite the promising reports on the use of daptomycin in 
pediatric patients, we forewent usage of this drug due to 
limited treatment experiences in children at our hospital.4
Since ceftaroline is not approved for use in children, 
information about appropriate ceftaroline dosage, safety, and 
efficacy in children is scarce.5,6 A study examining the safety 
of 3×12 mg/kg/d ceftaroline for pediatric patients of ,33 kg 
body weight has recently been completed, but its results have 
not been published yet.7 In a recent case report on ceftaro-
line treatment of MRSA pneumonia in a 6-year-old boy, a 
comparable initial dose of 2×9.7 mg/kg/d had been applied. 
During the course of treatment, the dosage was increased to 
3×10.8 mg/kg/d and it did not produce any side effects.8
With respect to body weight and the general condition of the 
patient described herein, initial therapy was started with a rela-
tively low dosage (2×9 mg/kg/d).9 As the postoperative course 
was satisfactory, the low-dose treatment was continued.
Within 4 days of treatment, the patient’s circulation 
stabilized and body temperature decreased, while C-reactive 
protein concentration and white blood cell count remained 
increased for another week, which was probably due to the 
extended wounds on her thighs. The patient’s temperature 
rose once again to 40.3°C, probably caused by dissemination 
of bacteria from the remaining infected tissue into circula-
tion. After a final revision surgery, inflammation parameters 
remained low.
In vitro analysis displayed an increased minimal inhibi-
tory concentration (MIC) of 1.5–4 mg/L for MRSA from 
blood culture, suggesting reduced antibiotic susceptibility 
to ceftaroline. Reduced preuse susceptibility to ceftaroline 
has been reported worldwide, predominantly in MRSA 
belonging to certain clonal lineages (ST228 and ST239).10 
The strains isolated in this case belong to a different clonal 
lineage (CC8); however, their isolation demonstrates that 
ceftaroline resistance might occur in MRSA in general.
Increased ceftaroline MICs reported in literature remain 
relatively low (1.5–4 mg/L) and it is not yet clear whether 
these MICs influence treatment efficiency. Therefore, 
changing the susceptibility interpretive criteria to an MIC 
of #2.0 mg/L was suggested recently based on pharmacoki-
netic and pharmacodynamic in vitro analyses.11 However, due 
to diagnostic challenges in susceptibility testing, ceftaroline 
MIC of 1.0 mg/L remains an important and conservative 
breakpoint to sensitize clinicians for putative treatment 
failure and to preserve ceftaroline as a potent antibiotic for 
serious infections caused by broadly resistant MRSA.10,12
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